Skip to main content
Deciphera
Deciphera
  • Patients & Caregivers
  • Healthcare Professionals
  • Clinical Studies
  • Presentations & Publications
  • News
twitter linkedin
  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • Tirabrutinib
    • Sapablursen
    • ONO-4578
    • ONO-2808
    • ONO-2020
    • DCC-3009
    • Inlexisertib
    • DCC-2812
    • ONO-4685
    • Expanded Access
  • Our Medicine
  • About
    • Management
  • Join Us
    • Open Positions
  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • Tirabrutinib
    • Sapablursen
    • ONO-4578
    • ONO-2808
    • ONO-2020
    • DCC-3009
    • Inlexisertib
    • DCC-2812
    • ONO-4685
    • Expanded Access
  • Our Medicine
  • About
    • Management
  • Join Us
    • Open Positions
  • Patients & Caregivers
  • Healthcare Professionals
  • Clinical Studies
  • Presentations & Publications
  • News
twitter linkedin
September 17 2021
Rebastinib
ESMO

A phase 1b/2 study of rebastinib and paclitaxel in advanced/metastatic platinum-resistant ovarian cancer.
Deciphera
twitter linkedin
contact us
  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • Tirabrutinib
    • Sapablursen
    • ONO-4578
    • ONO-2808
    • ONO-2020
    • DCC-3009
    • Inlexisertib
    • DCC-2812
    • ONO-4685
    • Expanded Access
  • Our Medicine
  • About
    • Management
  • Join Us
    • Open Positions
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Recruiting Privacy Policy
  • Web Accessibility Statement
  • Compliance Hotline
  • Consent Manager

© 2025 Deciphera Pharmaceuticals, LLC. The following are registered trademarks of Deciphera Pharmaceuticals, LLC: QINLOCK, the QINLOCK logo, DECIPHERA, and the Deciphera logo. The following are trademarks of Deciphera Pharmaceuticals, LLC: ROMVIMZA and the ROMVIMZA logo.

Back to top